Clinical practice guideline reveals limited evidence for treatments in immune thrombocytopenia, highlighting shared decision-making to minimize medication side effects.
There was a lack of evidence to support strong recommendations for various management approaches. In general, strategies that avoided medication side effects were favored. A large focus was placed on shared decision-making, especially with regard to second-line therapy. Future research should apply standard corticosteroid-dosing regimens, report patient-reported outcomes, and include cost-analysis evaluations.
No takes yet. Share an insight, caveat, or question.
Neunert et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: